Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARα) agonist Wy14,643

Cardiovascular Drug Reviews

Volumn 25, Issue 2, 2007, Pages 99-122

  Zahradka, Peter ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

Author keywords

Atherogenesis; Cardiac energetics; Hypolipidemic drugs; Pirinixic acid; PPAR ; Wy14,643

Indexed keywords

ANGIOTENSIN II; CYTOCHROME P450 ISOENZYME; FATTY ACID; FIBRIC ACID DERIVATIVE; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIRINIXIC ACID; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 3; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENERGY TRANSFER; FATTY ACID OXIDATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; LIVER; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PEROXISOME PROLIFERATORS; PYRIMIDINES;

EID: 34447136185     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2007.00008.x     Document Type: Review

References (152)

1. Aasum E, Cooper M, Severson DL, Larsen TS (2005) Effect of BM 17.0744, a PPARα ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol 83 : 183 190.
2. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M (1996) Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271 : 518 520.
3. Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM, Steffensen KR, Chandraratna RA, Gustafsson JA, Corton JC (2004a) Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver. Mol Pharmacol 66 : 1440 1452.
4. Anderson SP, Howroyd P, Liu J, Qian X, Bahnemann R, Swanson C, Kwak MK, Kensler TW, Corton JC (2004b) The transcriptional response to a peroxisome proliferator-activated receptor alpha agonist includes increased expression of proteome maintenance genes. J Biol Chem 279 : 52390 52398.
5. Andres V (2004) Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: New perspectives and therapeutic potential. Cardiovasc Res 63 : 11 21.
6. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ (1998) Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARα). J Biol Chem 273 : 5678 5684.
7. Badimon L, Martinez-Gonzalez J, Llorente-Cortes V, Rodriguez C, Padro T (2006) Cell biology and lipoproteins in atherosclerosis. Curr Mol Med 6 : 439 456.
8. Banfi C, Auwerx J, Poma F, Tremoli E, Mussoni L (2003) Induction of plasminogen activator inhibitor I by the PPARalpha ligand, Wy-14,643, is dependent on ERK1/2 signaling pathway. Thromb Haemost 90 : 611 619.
9. Barger PM, Kelly DP (2000) PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 10 : 238 245.
10. Bartles JR, Khuon S, Lin XH, Zhang LQ, Reddy JK, Rao MS, Isoye ST, Nehme CL, Fayos BE (1990) Peroxisome proliferator-induced alterations in the expression and modification of rat hepatocyte plasma membrane proteins. Cancer Res 50 : 669 676.
11. Beyer TP, Schmidt RJ, Foxworthy P, Zhang Y, Dai J, Bensch WR, Kauffman RF, Gao H, Ryan TP, Jiang XC, et al 2004) Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in mice: Effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. J Pharmacol Exp Ther 309 : 861 868.
12. Blake GJ, Ridker PM (2002) Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252 : 283 294.
13. Bulhak AA, Sjoquist PO, Xu CB, Edvinsson L, Pernow J (2006) Protection against myocardial ischaemia/reperfusion injury by PPAR-alpha activation is related to production of nitric oxide and endothelin-1. Basic Res Cardiol 101 : 244 252.
14. Buroker NE, Young ME, Wei C, Serikawa K, Ge M, Ning XH, Portman MA (2007) The dominant negative thyroid hormone receptor {beta} mutant {Delta}337T alters peroxisome proliferator-activated receptor {alpha} signaling in heart. Am J Physiol Endocrinol Metab 292 In press).
15. Cantor EJ, Babick AP, Vasanji Z, Dhalla NS, Netticadan T (2005) A comparative serial echocardiographic analysis of cardiac structure and function in rats subjected to pressure or volume overload. J Mol Cell Cardiol 38 : 777 786.
16. Chase AJ, Bond M, Crook MF, Newby AC (2002) Role of nuclear factor-kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 22 : 765 771.
17. Chatterjee B, Demyan WF, Lalwani ND, Reddy JK, Roy AK (1983) Reversible alteration of hepatic messenger RNA species for peroxisomal and non-peroxisomal proteins induced by the hypolipidaemic drug Wy-14,643. Biochem J 214 : 879 883.
18. Chen M, Masaki T, Sawamura T (2002) LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: Implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 95 : 89 100.
19. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart JC, Tedgui A, Najib-Fruchart J, et al 2000) CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101 : 2411 2417.
20. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B (1998) Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273 : 25573 25580.
21. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, et al 2001) PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 : 53 58.
22. Chiu RC, Tsang JC (1995) Biological perspective on "myocardial preconditioning J Card Surg 10 : 376 380.
23. Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, Gavrilova O, Reitman ML (2002) WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 277 : 24484 24489.
24. Choy PC, Siow YL, Mymin D, O K (2004) Lipids and atherosclerosis. Biochem Cell Biol 82 : 212 224.
25. Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, Fantozzi R (2006) Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: Effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med 41 : 579 589.
26. Corton JC, Apte U, Anderson SP, Limaye P, Yoon L, Latendresse J, Dunn C, Everitt JI, Voss KA, Swanson C, et al 2004) Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors. J Biol Chem 279 : 46204 46212.
27. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Centorrino T, Caputi AP (2004) Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. Lab Invest 84 : 1643 1654.
28. D'Atri G, Gomarasca P, Galimberti E, Sirtori CR, Kritchevsky D (1980) Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague-Dawley rats. Atherosclerosis 37 : 475 483.
29. Diep QN, Schiffrin EL (2001) Increased expression of peroxisome proliferator-activated receptor-alpha and-gamma in blood vessels of spontaneously hypertensive rats. Hypertension 38 : 249 254.
30. Djouadi F, Brandt JM, Weinheimer CJ, Leone TC, Gonzalez FJ, Kelly DP (1999) The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 60 : 339 343.
31. Dowell P, Peterson VJ, Zabriskie TM, Leid M (1997) Ligand-induced peroxisome proliferator-activated receptor alpha conformational change. J Biol Chem 272 : 2013 2020.
32. Durgan DJ, Smith JK, Hotze MA, Egbejimi O, Cuthbert KD, Zaha VG, Dyck JR, Abel ED, Young ME (2006) Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin. Am J Physiol Heart Circ Physiol 290 : H2480 H2497.
33. Eaton S (2002) Control of mitochondrial β-oxidation flux. Prog Lipid Res 41 : 197 239.
34. Fang X, Hu S, Watanabe T, Weintraub NL, Snyder GD, Yao J, Liu Y, Shyy JY, Hammock BD, Spector AA (2005) Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 314 : 260 270.
35. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45 : 120 159.
36. Finck BN (2004) The role of the peroxisome proliferator-activated receptor alpha pathway in pathological remodeling of the diabetic heart. Curr Opin Clin Nutr Metab Care 7 : 391 396.
37. Finck BN, Kelly DP (2002) Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 34 : 1249 1257.
38. Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94 : 4312 4317.
39. Gervois P, Vu-Dac N, Kleemann R, Kockx M, Dubois G, Laine B, Kosykh V, Fruchart JC, Kooistra T, Staels B (2001) Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem 276 : 33471 33477.
40. Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, et al 2005) PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest 115 : 3228 3238.
41. Goel SK, Lalwani ND, Fahl WE, Reddy JK (1985) Lack of covalent binding of peroxisome proliferators nafenopin and Wy-14 643 to DNA in vivo and in vitro. Toxicol Lett 24 : 37 43.
42. Goetze S, Eilers F, Bungenstock A, Kintscher U, Stawowy P, Blaschke F, Graf K, Law RE, Fleck E, Grafe M (2002) PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 293 : 1431 1437.
43. Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S, Saito H, Kouhara H, Kasayama S, Kawase I (2004) Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 24 : 658 663.
44. Green S (1995) PPAR: A mediator of peroxisome proliferator action. Mutat Res 333 : 101 109.
45. Hamano T, Kobayashi K, Sakairi T, Hayashi M, Mutai M (2001) Peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, WY-14,643, increased transcription of myosin light chain-2 in cardiomyocytes. J Toxicol Sci 26 : 275 284.
46. Han SH, Quon MJ, Koh KK (2005) Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 46 : 1086 1092.
47. Hardie DG, Hawley SA, Scott JW (2006) AMP-activated protein kinase-development of the energy sensor concept. J Physiol 574 : 7 15.
48. Hashimoto K, Cohen RN, Yamada M, Markan KR, Monden T, Satoh T, Mori M, Wondisford FE (2006) Cross-talk between thyroid hormone receptor and liver X receptor regulatory pathways is revealed in a thyroid hormone resistance mouse model. J Biol Chem 281 : 295 302.
49. Hayashida K, Kume N, Minami M, Kataoka H, Morimoto M, Kita T (2001) Peroxisome proliferator-activated receptor a ligands increase lectin-like oxidized low density lipoprotein receptor-1 expression in vascular endothelial cells. Ann N Y Acad Sci 947 : 370 372.
50. Hu ZW, Kerb R, Shi XY, Wei-Lavery T, Hoffman BB (2002) Angiotensin II increases expression of cyclooxygenase-2: Implications for the function of vascular smooth muscle cells. J Pharmacol Exp Ther 303 : 563 573.
51. Huss JM, Kelly DP (2004) Nuclear receptor signaling and cardiac energetics. Circ Res 95 : 568 578.
52. Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, Schiffrin EL (2003) Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 42 : 737 743.
53. Inoue I, Shino K, Noji S, Awata T, Katayama S (1998) Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246 : 370 374.
54. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I (2003) Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38 : 123 132.
55. Irukayama-Tomobe Y, Miyauchi T, Sakai S, Kasuya Y, Ogata T, Takanashi M, Iemitsu M, Sudo T, Goto K, Yamaguchi I (2004) Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation 109 : 904 910.
56. Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 : 645 650.
57. Ivashchenko Y, Kramer F, Schafer S, Bucher A, Veit K, Hombach V, Busch A, Ritzeler O, Dedio J, Torzewski J (2005) Protein kinase C pathway is involved in transcriptional regulation of C-reactive protein synthesis in human hepatocytes. Arterioscler Thromb Vasc Biol 25 : 186 192.
58. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 : 82 86.
59. Kanda S, Kuzuya M, Ramos MA, Koike T, Yoshino K, Ikeda S, Iguchi A (2000) Matrix metalloproteinase and alphavbeta3 integrin-dependent vascular smooth muscle cell invasion through a type I collagen lattice. Arterioscler Thromb Vasc Biol 20 : 998 1005.
60. Kantor PF, Dyck JR, Lopaschuk GD (1999) Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci 318 : 3 14.
61. Kaperonis EA, Liapis CD, Kakisis JD, Dimitroulis D, Papavassiliou VG (2006) Inflammation and atherosclerosis. Eur J Vasc Endovasc Surg 31 : 386 393.
62. Kawabe K, Saegusa H, Seto K, Urabe H, Motojima K (2005) Peroxisome proliferator-activated receptor alpha and its response element are required but not sufficient for transcriptional activation of the mouse heart-type fatty acid binding protein gene. Int J Biochem Cell Biol 37 : 1534 1546.
63. Keller BJ, Bradford BU, Marsman DS, Cattley RC, Popp JA, Bojes HK, Thurman RG (1993) The nongenotoxic hepatocarcinogen Wy-14,643 is an uncoupler of oxidative phosphorylation in vivo. Toxicol Appl Pharmacol 119 : 52 58.
64. Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, et al 2003) Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52 : 1770 1778.
65. Kintscher U, Lyon C, Wakino S, Bruemmer D, Feng X, Goetze S, Graf K, Moustakas A, Staels B, Fleck E, et al 2002) PPARalpha inhibits TGF-β-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. Circ Res 91 : e35-e44.
66. Kita T, Kume N, Minami M, Hayashida K, Murayama T, Sano H, Moriwaki H, Kataoka H, Nishi E, Horiuchi H, et al 2001) Role of oxidized LDLs in atherosclerosis. Ann N Y Acad Sci 947 : 199 205.
67. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T (2004) Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103 : 4188 4194.
68. Knauf C, Rieusset J, Foretz M, Cani PD, Uldry M, Hosokawa M, Martinez E, Bringart M, Waget A, Kersten S, et al 2006) Peroxisome proliferator-activated receptor-α-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: Role in liver and brain. Endocrinology 147 : 4067 4078.
69. Knight BL, Hebbachi A, Hauton D, Brown AM, Wiggins D, Patel DD, Gibbons GF (2005) A role for PPARα in the control of SREBP activity and lipid synthesis in the liver. Biochem J 389 : 413 421.
70. Kobori H, Ozawa Y, Suzaki Y, Nishiyama A (2005) Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol 16 : 2073 2080.
71. Kooistra T, Verschuren L, de Vries-van der Weij, Koenig W, Toet K, Princen HM, Kleemann R (2006) Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: Evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol 26 : 2322 2330.
72. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11 : 779 791.
73. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL (2001) Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 104 : 448 454.
74. Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T, Kita T (1998) Inducible expression of lectin-like oxidized LDLs receptor-1 in vascular endothelial cells. Circ Res 83 : 322 327.
75. Lalwani ND, Alvares K, Reddy MK, Reddy MN, Parikh I, Reddy JK (1987) Peroxisome proliferator-binding protein: Identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver. Proc Natl Acad Sci U S A 84 : 5242 5246.
76. Lalwani ND, Reddy MK, Qureshi SA, Reddy JK (1981) Development of hepatocellular carcinomas and increased peroxisomal fatty acid beta-oxidation in rats fed [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in the semipurified diet. Carcinogenesis 2 : 645 650.
77. Lazarow PB (1977) Three hypolipidemic drugs increase hepatic palmitoyl-coenzyme A oxidation in the rat. Science 197 : 580 581.
78. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15 : 3012 3022.
79. Lee WY, Allison MA, Kim DJ, Song CH, Barrett-Connor E (2007) Association of interleukin-6 and C-reactive protein with aubclinical carotid atherosclerosis (the Rancho Bernardo Study). Am J Cardiol 99 : 99 102.
80. Lefebvre P, Chinetti G, Fruchart JC, Staels B (2006) Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 116 : 571 580.
81. Lehman JJ, Kelly DP (2002) Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev 7 : 175 185.
82. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272 : 3406 3410.
83. Li L, Wu L, Wang C, Liu L, Zhao Y (2007) Adiponectin modulates carnitine palmitoyltransferase-1 through AMPK signaling cascade in rat cardiomyocytes. Regul Pept 139 : 72 79.
84. Liang F, Wang F, Zhang S, Gardner DG (2003) Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology 144 : 4187 4194.
85. Libby P (2000) Changing concepts of atherogenesis. J Intern Med 247 : 349 358.
86. Litwak KN, Cefalu WT, Wagner JD (1998) Chronic hyperglycemia increases arterial low-density lipoprotein metabolism and atherosclerosis in cynomolgus monkeys. Metabolism 47 : 947 954.
87. Lopaschuk GD (2002) Metabolic abnormalities in the diabetic heart. Heart Fail Rev 7 : 149 159.
88. Lusis AJ (2000) Atherosclerosis. Nature 407 : 233 241.
89. Malinow MR (1981) Dietary and pharmacologic control of atherosclerosis regression in cynomolgus macaques (Macaca fascicularis). Artery 9 : 12 20.
90. Mandard S, Muller M, Kersten S (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61 : 393 416.
91. Marx N, Duez H, Fruchart JC, Staels B (2004) Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ Res 94 : 1168 1178.
92. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J (1998) Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83 : 1097 1103.
93. Mills J, Mansfield M, Grant P (2002) Elevated fibrinogen in the healthy male relatives of patients with severe, premature coronary artery disease. Eur Heart J 23 : 1276 1281.
94. Milton MN, Elcombe CR, Kass GE, Gibson GG (1988) Lack of evidence for a hepatic peroxisome proliferator receptor and an explanation for the binding of hypolipidaemic drugs to liver homogenates. Biochem Pharmacol 37 : 793 798.
95. Mochizuki K, Suruga K, Fukami H, Kiso Y, Takase S, Goda T (2006) Selectivity of fatty acid ligands for PPARalpha which correlates both with binding to cis-element and DNA binding-independent transactivity in Caco-2 cells. Life Sci 80 : 140 145.
96. Moncada S (2006) Adventures in vascular biology: A tale of two mediators. Philos Trans R Soc Lond B Biol Sci 361 : 735 759.
97. Moody DE, Reddy JK (1978) The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-associated enzymes. Am J Pathol 90 : 435 450.
98. Moody DE, Reddy JK, Azarnoff DL (1984) Peroxisome-associated enzymes and serum lipids in tumour-bearing rats treated with peroxisome-proliferating agents. Biochem Pharmacol 33 : 2591 2597.
99. Munro E, Patel M, Chan P, Betteridge L, Gallagher K, Schachter M, Wolfe J, Sever P (1994) Growth inhibition of human vascular smooth muscle cells by fenofibrate: A possible therapy for restenosis. Cardiovasc Res 28 : 615 620.
100. Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T, Hirai T, Numaguchi Y, Okumura K, Seo H, et al 2006) Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun 341 : 973 978.
101. Murakami K, Ide T, Suzuki M, Mochizuki T, Kadowaki T (1999) Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha. Biochem Biophys Res Commun 260 : 609 613.
102. Murray AJ, Panagia M, Hauton D, Gibbons GF, Clarke K (2005) Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes 54 : 3496 3502.
103. Nakagawa K, Holla VR, Wei Y, Wang WH, Gatica A, Wei S, Mei S, Miller CM, Cha DR, Price E Jr., et al 2006) Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest 116 : 1696 1702.
104. Newby AC, Zaltsman AB (2000) Molecular mechanisms in intimal hyperplasia. J Pathol 190 : 300 309.
105. Ng VY, Morisseau C, Falck JR, Hammock BD, Kroetz DL (2006) Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol 26 : 2462 2468.
106. Okamoto K, Tabei R, Fukushima M, Nosaka S, Yamori Y (1966) Further observations of the development of a strain of spontaneously hypertensive rats. Jpn Circ J 30 : 703 716.
107. Parmentier JH, Lavrentyev EN, Falck JR, Capdevila JH, Malik KU (2005) Evaluation of cytochrome P450 4 family as mediator of phospholipase D activation in aortic vascular smooth muscle cells. Life Sci 77 : 1015 1029.
108. Parthasarathy S, Kritchevsky D, Baumann WJ (1982) Hypolipidemic drugs are inhibitors of phosphatidylcholine synthesis. Proc Natl Acad Sci U S A 79 : 6890 6893.
109. Patsouris D, Reddy JK, Muller M, Kersten S (2006) Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147 : 1508 1516.
110. Piper HM, Meuter K, Schafer C (2003) Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg 75 : S644 S648.
111. Piro M, Giubilato G, Pinnelli M, Giordano SP, Biasucci LM (2005) Endothelium and inflammation. Panminerva Med 47 : 75 80.
112. Planavila A, Calvo RR, Vazquez-Carrera M (2006) Peroxisome proliferator-activated receptors and the control of fatty acid oxidation in cardiac hypertrophy. Mini Rev Med Chem 6 : 357 363.
113. Poynter ME, Daynes RA (1998) Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273 : 32833 32841.
114. Raines EW, Ferri N (2005) Thematic review series: the immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 46 : 1081 1092.
115. Raines EW, Ross R (1993) Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J 69 : S30 S37.
116. Rao MS, Reddy JK (1987) Peroxisome proliferation and hepatocarcinogenesis. Carcinogenesis 8 : 631 636.
117. Reddy JK, Moody DE, Azarnoff DL, Tomarelli RM (1977) Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse. Arch Int Pharmacodyn Ther 225 : 51 57.
118. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, Junquero D, Colpaert FC, Delhon A (2002) PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435 : 143 151.
119. Rosenthal J (1993) Role of renal and extrarenal renin-angiotensin system in the mechanism of arterial hypertension and its sequelae. Steroids 58 : 566 572.
120. Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD (2006) Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 290 : H87 H95.
121. Samuel P, Holtzman CM, Meilman E, Sekowski I (1970) Reduction of serum cholesterol and triglyceride levels by the combined administration of neomycin and clofibrate. Circulation 41 : 109 114.
122. Sanders M (1994) Molecular and cellular concepts in atherosclerosis. Pharmacol Ther 61 : 109 153.
123. Santilli AA, Scotese AC, Tomarelli RM (1974) A potent antihypercholesterolemic agent: (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio) acetic acid (Wy-14643). Experientia 30 : 1110 1111.
124. Schiffrin EL (2005) Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 288 : H1037 H1043.
125. Schrauwen P, Hoeks J, Hesselink MK (2006) Putative function and physiological relevance of the mitochondrial uncoupling protein-3: Involvement in fatty acid metabolism? Prog Lipid Res 45 : 17 41.
126. Schulman IH, Zhou MS, Raij L (2006) Interaction between nitric oxide and angiotensin II in the endothelium: Role in atherosclerosis and hypertension. J Hypertens Suppl 24 : S45 S50.
127. Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, Voegel JJ, Vignon F, Nicolas JC, Balaguer P (2005) Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem 344 : 8 15.
128. Selim E, Frkanec JT, Cunard R (2007) Fibrates upregulate TRB3 in lymphocytes independent of PPARalpha by augmenting CCAAT/enhancer-binding proteinbeta (C/EBPbeta) expression. Mol Immunol 44 : 1218 1229.
129. Singh I (1997) Biochemistry of peroxisomes in health and disease. Mol Cell Biochem 167 : 1 29.
130. Sivarajah A, Chatterjee PK, Hattori Y, Brown PA, Stewart KN, Todorovic Z, Mota-Filipe H, Thiemermann C (2002) Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit 8 : BR532 BR539.
131. Sluse FE, Jarmuszkiewicz W, Navet R, Douette P, Mathy G, Sluse-Goffart CM (2006) Mitochondrial UCPs: New insights into regulation and impact. Biochim Biophys Acta 1757 : 480 485.
132. Spencer NF, Poynter ME, Im SY, Daynes RA (1997) Constitutive activation of NF-kappa B in an animal model of aging. Int Immunol 9 : 1581 1588.
133. Srinivasan S, Hatley ME, Reilly KB, Danziger EC, Hedrick CC (2004) Modulation of PPARalpha expression and inflammatory interleukin-6 production by chronic glucose increases monocyte/endothelial adhesion. Arterioscler Thromb Vasc Biol 24 : 851 857.
134. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, et al 1998) Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 : 790 793.
135. Stavinoha MA, RaySpellicy JW, Essop MF, Graveleau C, Abel ED, Hart-Sailors ML, Mersmann HJ, Bray MS, Young ME (2004) Evidence for mitochondrial thioesterase 1 as a peroxisome proliferator-activated receptor-alpha-regulated gene in cardiac and skeletal muscle. Am J Physiol Endocrinol Metab 287 : E888 E895.
136. Suga T (2004) Hepatocarcinogenesis by peroxisome proliferators. J Toxicol Sci 29 : 1 12.
137. Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R (2002) Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol 2 : 10.
138. Vanden Heuvel JP, Kreder D, Belda B, Hannon DB, Nugent CA, Burns KA, Taylor MJ (2003) Comprehensive analysis of gene expression in rat and human hepatoma cells exposed to the peroxisome proliferator WY14,643. Toxicol Appl Pharmacol 188 : 185 198.
139. Vu-Dac N, Gervois P, Jakel H, Nowak M, Bauge E, Dehondt H, Staels B, Pennacchio LA, Rubin EM, Fruchart-Najib J, et al 2003) Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 278 : 17982 17985.
140. Wang Y, Botolin D, Xu J, Christian B, Mitchell E, Jayaprakasam B, Nair MG, Peters JM, Busik JV, Olson LK, et al 2006) Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J Lipid Res 47 : 2028 2041.
141. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16 : 1027 1040.
142. Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: From orphan receptors to drug discovery. J Med Chem 43 : 527 550.
143. Willson TM, Wahli W (1997) Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1 : 235 241.
144. Wu L, Wang R, De Champlain J, Wilson TW (2004) Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am J Hypertens 17 : 749 756.
145. Yeh CH, Chen TP, Lee CH, Wu YC, Lin YM, Lin PJ (2006) Cardiomyocytic apoptosis following global cardiac ischemia and reperfusion can be attenuated by peroxisome proliferator-activated receptor alpha but not gamma activators. Shock 26 : 262 270.
146. Young ME, Patil S, Ying J, Depre C, Ahuja HS, Shipley GL, Stepkowski SM, Davies PJ, Taegtmeyer H (2001) Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. FASEB J 15 : 833 845.
147. Zahradka P, Wright B, Fuerst M, Yurkova N, Molnar K, Taylor CG (2006) Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration. J Pharmacol Exp Ther 317 : 651 659.
148. Zahradka P, Yurkova N, Litchie B, Moon MC, Del Rizzo DF, Taylor CG (2003) Activation of peroxisome proliferator-activated receptors alpha and gamma-1 inhibits human smooth muscle cell proliferation. Mol Cell Biochem 246 : 105 110.
149. Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B (2006) Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 26 : 977 986.
150. Zhou S, Wallace KB (1999) The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol Sci 48 : 82 89.
151. Zhu S, Su G, Meng QH (2006) Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin Chem 52 : 2036 2042.
152. Zungu M, Felix R, Faadiel EM (2006) Wy-14,643 and fenofibrate inhibit mitochondrial respiration in isolated rat cardiac mitochondria. Mitochondrion 6 : 315 322.